EGFR and non-small cell lung carcinoma: For patients with EGFR-mutated NSCLC who develop MPE, treatment strategies involving third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) or sequential first- followed by third-generation EGFR-TKIs have been shown to further extend survival (10).